Table II.

Differences in the prognosis and risk factors of patients with or without Candida-positive cultures.

Factors	Candidemia, n	Non-candidemia, n	P-value	RR (95% CI)	Odds ratio (95% CI)
Underlying disease
GI dysfunctions	11/19	2/21	0.0001b	2.86 (1.537–5.34)	13.06 (2.34–72.85)
Risk factor
Prior use of antibiotics >2 weeks	17/19	1/21	<0.0001c	10.39 (2.76–39.14)	170 (14.00–2044)
>3 types of antibiotics	11/19	2/21	0.0019b	2.86 (1.53–5.34)	13.06 (2.34–72.85)
Carbapenems	13/19	3/21	0.0009c	3.250 (1.56–6.758)	13 (2.734–61.81)
Glycopeptides	10/19	1/21	0.001b	2.93 (1.65–5.20)	22.22 (2.46–200.90)
Nitroimidazoles	8/19	1/21	0.0072b	2.51 (1.48–4.25)	14.55 (1.60–132.00)
Central venous cannula	16/19	2/21	<0.0001c	6.52 (2.25–18.90)	50.67 (7.51–341.90)
Parenteral nutrition >2 weeks	16/19	2/21	<0.0001c	6.52 (2.25–18.90)	50.67 (7.51–341.90)
GI surgery	9/19	2/21	0.0123a	2.37 (1.33–4.21)	8.55 (1.54–47.43)
Repeated endotracheal intubation	7/19	0/21	0.0027b	2.75 (1.75–4.32)	25.80 (1.35–491.50)
Secondary GI surgery	7/19	0/21	0.0027b	2.75 (1.75–4.32)	25.80 (1.35–491.50)
Maternal candidal vaginitis	4/19	0/21	0.0424a	2.40 (1.63–3.53)	12.48 (0.62–249.40)
Prognosis
Hospital mortality	3/19	0/21	0.098		9.1 (0.43–189.3)
90-day mortality	5/19	1/21	0.056	5.53 (0.71–43.18)	7.14 (0.75–68.01)
Growth retardation at 6 months after discharge	11/19	1/21	0.001b	2.93 (1.65–5.20)	22.22 (2.46–200.90)

^aP=0.01–0.05

^bP=0.001–0.01

^cP<0.001. RR, relative risk; CI, confidence interval; GI, gastrointestinal.